Loading...
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 ex...
Na minha lista:
| Udgivet i: | Leukemia |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7584476/ https://ncbi.nlm.nih.gov/pubmed/32733012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0996-5 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|